Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Apadamtase Alfa

Recombinant protein · Protein replacement: von Willebrand factor (VWF) · developed by Takeda

N/A Most advanced trial
TAK Developer

What is Apadamtase Alfa?

Apadamtase alfa is a recombinant human ADAMTS13 enzyme that cleaves von Willebrand factor at the Tyr1605-Met1606 bond in the A2 domain, reducing ultralarge VWF multimers that drive platelet binding. It is being studied in thrombotic thrombocytopenic purpura (TTP).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Recombinant ADAMTS13
Drug type
Recombinant protein
Targets
von Willebrand factor (VWF)
Mechanism
Protein replacement: von Willebrand factor (VWF)
Pathways
VWF multimer proteolysis, platelet adhesion, blood coagulation
Therapy area
Hematology
Developer
Takeda (TAK)
FDA status
Investigational, not approved in the US. Most advanced trial: N/A
UNII
U5SFU33XUX

Conditions studied

Thrombotic Thrombocytopenic Purpura (TTP)

More from Takeda

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the TAK page.

Follow TAK, the company behind Apadamtase Alfa

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.